Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Rusnano Invests In Cleveland BioLabs
by Ann M. Thayer
October 3, 2011
| A version of this story appeared in
Volume 89, Issue 40
Cleveland BioLabs will launch an oncology-focused subsidiary called Panacela Labs with support from the Russian Corporation of Nanotechnologies. Rusnano will invest $9 million up front and up to $26 million over four years contingent on development and investment milestones. In addition to contributing five drug candidates, Cleveland BioLabs will invest $3 million and own about 55% of Panacela. Other intellectual property will come from Roswell Park Cancer Institute, Cleveland Clinic Foundation, and Children’s Cancer Institute, in Australia. Panacela will first seek approval of any drugs in Russia. Rusnano recently invested in Pro Bono Bio in the U.K. (C&EN, Sept. 19, page 8).
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X